RxDoctor Payments Data

Susana Vasseur, MD

Internal Medicine · Pembroke Pines, FLNPI 1275945289

Payments from drug & device makers

$497in general payments, 2019–2025

Across 24 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$205
  • Lilly USA, LLC$80
  • AstraZeneca$49
  • Janssen Scientific Affairs, LLC$38
  • Pfizer$34
  • Abbott$22
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$497 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$8,779
Medicare patients
13
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin162$215,403
RybelsusSemaglutide110$146,550
OzempicSemaglutide105$131,473
EliquisApixaban120$102,150
FarxigaDapagliflozin Propanediol76$59,069
MounjaroTirzepatide41$44,699
XareltoRivaroxaban32$42,588
JanuviaSitagliptin Phosphate17$27,746
MyrbetriqMirabegron32$26,985
TrulicityDulaglutide17$16,429
LinzessLinaclotide29$16,426
SymbicortBudesonide/Formoterol Fumarate44$9,964
Tresiba Flextouch U-100Insulin Degludec31$9,296
VascepaIcosapent Ethyl23$9,218
Spiriva HandihalerTiotropium Bromide13$8,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$16$278,023215 claims
Boehringer IngelheimJardiance$205$215,403162 claims
PfizerEliquis$34$102,150120 claims
AstraZenecaFarxiga, Symbicort$49$69,033120 claims
Lilly USA, LLCMounjaro, Trulicity$80$61,12858 claims
AbbVieLinzess, Restasis, Synthroid$14$28,50181 claims
Astellas Pharma US IncMyrbetriq$22$26,98532 claims
GSKBreo Ellipta$16$4,53111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →